Viewing Study NCT00722293

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:24 AM
Ignite Modification Date: 2026-01-31 @ 10:12 PM
Study NCT ID: NCT00722293
Status: COMPLETED
Last Update Posted: 2017-11-13
First Post: 2008-07-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms, Breast View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Solid tumors View
None Cancer View
None Neoplasms, Ovarian View
None doxorubicin View
None epirubicin View
None anti-angiogenesis View
None pharmacodynamics View
None pazopanib (GW786034) View
None pharmacokinetics View
None Soft Tissue View
None Sarcoma View